---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-018143"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2022-04-05T23:59:59+00:00"
generated_at: "2026-06-26T09:29:39.097291+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Longeveron appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer effective April 4, 2022

## Summary
- Dr. Min will lead global clinical development and regulatory strategy; focus on advancing Lomecel-B into pivotal trials and approval.
- Compensation: base salary $350k, performance bonus 30%, $60k signing bonus (half RSUs, half options), plus 150k RSUs and 50k stock options vesting over 4 years.
- Dr. Min brings over a decade of pharma/biotech experience including roles at Merck, Cerevel, BlueRock, and Enterin; board-certified neurologist.
- Annual shareholder meeting set for June 24, 2022; proposal deadlines: Rule 14a-8 proposals due May 6, other business notice due June 17.

## SEC filing metadata
- accession: 0001213900-22-018143
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2022-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/0001213900-22-018143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/ea158049-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-018143
- JSON: https://secwatch.observer/filing/0001213900-22-018143.json
- Plain text: https://secwatch.observer/filing/0001213900-22-018143.txt

## Key facts
- Executive change
  K. Chris Min, M.D., Ph.D. was appointed as Chief Medical Officer at Longeveron Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On April 5, 2022, Longeveron Inc. (“Longeveron”) announced the appointment of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/0001213900-22-018143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.